GCA
BLUE

Gideon Capital Advisors’s bluebird bio BLUE Stock Holding History

Gideon Capital Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-143
Closed -$330K – 350
2017
Q4 		$330K Buy
+143
New +$290K 0.29% 134

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Gideon Capital Advisors's BLUE Position: Q1 2018 in Review

Gideon Capital Advisors sold out of bluebird bio (BLUE) in Q1 2018, closing a stake of 143 shares — an estimated $330K sold.

Gideon Capital Advisors first reported a position in BLUE in Q4 2017 and held it in 1 quarter. The position peaked at $330K in Q4 2017. 303 funds tracked by Wall St. Rank hold BLUE as of Q1 2018.

  • Gideon Capital Advisors reported no remaining bluebird bio position as of Q1 2018 after selling out during the quarter.
  • Gideon Capital Advisors sold 143 bluebird bio shares in Q1 2018, an estimated $330K.
  • Gideon Capital Advisors first reported a position in bluebird bio in Q4 2017 and held it in 1 quarter.
  • Gideon Capital Advisors's bluebird bio position peaked at $330K in Q4 2017.
  • 303 funds tracked by Wall St. Rank held bluebird bio as of Q1 2018.

Based on Gideon Capital Advisors's 13F filing for Q1 2018, filed 14 May 2018.